Genetic associations of the sclerostin pQTLs with cardiovascular events and risk factors in the datasets in Table 2.2 that were analysed by Zheng et al. (2023) (or equivalent1).
Table 5.2: GWAS associations with sclerostin pQTLs (additional datasets)
qq_plot(assoc_add)
Figure 5.2: QQ plot of GWAS associations with sclerostin pQTLs (additional datasets)
Kavousi M, Bos MM, Barnes HJ, et al. Multi-ancestry genome-wide analysis identifies effector genes and druggable pathways for coronary artery calcification. medRxiv. 2022;2022–05.
Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nature genetics. 2018;50(4):524–37.
Malik R, Traylor M, Pulit SL, et al. Low-frequency and common genetic variation in ischemic stroke: The METASTROKE collaboration. Neurology. 2016;86(13):1217–26.
Zheng J, Wheeler E, Pietzner M, et al. Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: Evidence from a genome-wide association meta-analysis followed by mendelian randomization. Arthritis & Rheumatology. 2023;75(10):1781–92.
The ischemic and cardioembolic stroke GWAS results from METASTROKE (Malik et al. 2016) used by Zheng et al. (2023) were replaced with those from MEGASTROKE (Malik et al. 2018) and the UK Biobank hypertension GWAS results from OpenGWAS used by Zheng et al. (2023) were replaced with those from Pan-UKBB due to licensing restrictions. The GWAS of coronary artery calcification was not available either publicly or via application at the time of this analysis (Kavousi et al. 2022).↩︎